Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was INR 1.64 million compared to INR 267.99 million a year ago. Net loss was INR 49.18 million compared to INR 30.83 million a year ago. Basic loss per share from continuing operations was INR 1.14 compared to INR 0.71 a year ago. Diluted loss per share from continuing operations was INR 1.14 compared to INR 0.71 a year ago.
For the six months, revenue was INR 2.65 million. Net loss was INR 95.06 million. Basic loss per share from continuing operations was INR 2.2. Diluted loss per share from continuing operations was INR 2.2.